anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The invention relates to a process for the preparation of a pharmaceutical preparation for oral administration, comprising a storable suspension of viable eggs of parasitic helminths which are nonpathogenic to humans. viz. Trichuris suis, where, after the ingestion of the suspension, a sufficient number of helminths develops to result in a stimulation of regulatory human T-cells. The suspension of the helminth eggs is subjected, in one step, to an acid treatment at a pH of &lt;=2 and in that, in a further step, the pH is adjusted to &gt;=4 and a pharmacologically acceptable preservative is added. The invention further relates to a pharmaceutical preparation for oral administration, comprising a storable suspension of viable eggs of parasitic helminths which are nonpathogenic to humans, viz. Trichuris suis, where, after the ingestion of the suspension, a sufficient number of helminths develops to result in a stimulation of regulatory T-cells, the suspension comprising fewer than 1000 colony-forming microorganisms per ml of suspension, the pharmaceutical preparation is prepared by the process as claimed.
PROBLEM TO BE SOLVED: To obtain a water-based preparation most suitable for the production of hair-treatment, shower bath or shower gel, etc., by combining an alkylpolyglycoside with a specific compound and optionally adding a surfactant to the mixture. SOLUTION: An alkylpolyglycoside is used in combination with a polyethylene glycol ether derivative of formula I (R&lt;1&gt; is an 8-22C alkyl; A is a bivalent group derived from diisocyanate; (n) is 20-400). The alkylpolyglycoside is preferably a compound of formula II (R&lt;2&gt; is an 8-18C straight or branched-chain alkyl; G is a polyglycosyl group; (m) is 1.5 to 5). The system is preferably further incorporated with a surfactant (e.g. a fatty alcohol ether sulfate). The water- based preparation is preferably produced by compounding 1-20wt.% of the alkylpolyglycoside and 0.05-1wt.% of the polyethylene glycol ether derivative of formula I.
503,633. Preparations of medicinal plants. MADAUS, G., MADAUS, F., and MADAUS, H., (trading as MADAUS &amp; CO., DR.). Nov. 6, 1937, No. 30499. Convention date, Dec. 19, 1936. [Class 81 (i)] Preparations of medicinal plants are obtained by finely triturating fresh plants or parts thereof with an insoluble inorganic adsorbent and gradually drying the product in a current of cool air, substances of alkaline reaction being added prior to drying and preferably prior to the trituration. Volatile oils and other constituents present in the plants are retained in the dry products. Adsorbents referred to are colloidal silica, loam, kaolin, fuller&#39;s earth, aluminium hydroxide. Alkaline substances referred to are carbonates, bicarbonates and hydroxides of alkali metals or alkaline earths, and alkaline buffer salts or mixtures thereof, particularly such salts as contain the same acid constituents as those naturally present in the plants. Amorphous carbohydrates or carbohydrate derivatives, such as pectin, swollen starch, tragacanth, amyloses and dextrin may also be added. Examples relate : (1) to treatment of thuja with clay and sodium bicarbonate; (2) to treatment of sabina with loam, sodium bicarbonate and pectin; and (3) to treatment of cortex salicis with loess and disodium phosphate. The products are dried to a 2 per cent moisture content by means of a.current of air at a temperature not exceeding 30‹ C. Specification 485,188 is referred to.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain an optical coloring body for a non-toxic and chemically stable cosmetic composition by utilizing a principle except a coloration method by absorption of a part of light like a conventional colorant such as pigment, coloring matter, dye, etc., and utilizing colloidal microcrystal of spherical nano fine particle developing a clear structural color observed in all directions and its cosmetic composition.  &lt;P&gt;SOLUTION: The optical coloring body comprises a liquid medium and micelles including colloidal microcrystal of flocculated spherical nano fine particles of single substance and same particle diameters. The micelle-forming agent of the micelle is reinforced by a polymer. The cosmetic composition is colored by the optical coloring body. The colloidal microcrystal of spherical nano fine particle of the optical coloring body selectively reflects, refracts and interferes light and develops of a color of light of specific wavelength under light irradiation by a photonic band effect.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PURPOSE:To obtain a new polypeptide, especially an epitope of an endogenous stress protein. CONSTITUTION:A polypeptide having an amino acid sequence shown by the formula or the biologically same amino acid sequence as the sequence or its polymer. Length of sequence: 11. Type of sequence: amino acid. Topology: straight chain. Kind of sequence: peptide. The polypetide is usable for a vaccine for treating Kawasaki&#39;s disease, an antagonist for enhancing factor, an antigen in measuring an antibody contained in serum of patient of Kawasaki&#39;s disease or for monitoring in a critical stage of the disease.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide the use of at least one set of peptides in compositions and a method for modulating an immune response to one or a plurality of polypeptide antigens.  &lt;P&gt;SOLUTION: A method for using a specific peptide antigen in a range of preventive, diagnostic and therapeutic applications is provided. The sequences in a respective set of peptides are derived in whole, or in part, from a single polypeptide antigen. Individual peptides in the respective set of the peptides comprise different portions of an amino acid sequence corresponding to the single polypeptide antigen and display partial sequence identity or similarity to at least one other peptide of the same set of peptides. Furthermore, there is provided the use of uncultured antigen-presenting cells or precursors thereof, which have not been subjected to activating conditions and have been contacted with an antigen, in methods and compositions for modulating immune response in a recipient of those cells.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
A networked computer-based system, method, and computer program product for providing care to an infant is disclosed. First data is received through a first communication path at an event server from a first device. The first device may be a childcare device or the first device may be a user device, such as a user&#39;s cellular telephone, networked personal computing device, or a health/sleep monitor. The event server also receives second data from a second device through a second communication path. The first communication path and the second communication path being at least partially different. The second communication device may be childcare device. The event server determines whether to send a control signal to a controllable childcare device or send a control signal to controllable childcare device. The event server uses the first and second data and applies the data to predetermined logic to determine a result. A control signal is sent to the controllable childcare device for changing the state of the childcare device and causing it to assume a different behavior. In the alternative, an alarm message is sent to the personal computing device of a caregiver based upon the result.
PURPOSE:To prepare a cosmetic for hair, capable of improving the moisture- retaining function of hair and thereby applying a smooth and wet touch to hair, and keeping an excellent effect, e.g. prevention of damage to hair for a long period. CONSTITUTION:This is a new cosmetic for hair, containing 0.001 to 10wt.% magnesium compound (especially a magnesium halide or magnesium salt of an oxyacid is preferably used) and 0.01 to 10wt.% one or more kinds of cationic surfactants in combination and capable of improving especially the moisture- retaining function of hairs. As the cationic surfactant, a quaternary ammonium salt type cationic surfactant represented by the formula (R&lt;3&gt; and R&lt;4&gt; are each methyl, ethyl or a polyoxyethylene; R&lt;1&gt; and R&lt;2&gt; are each an alkyl or an alkenyl, atherovise, R&lt;1&gt; may be an alkyl or an alkenyl and R&lt;2&gt; may be methyl, ethyl, etc.; X is a halogen, methylsulfate residue, etc.) is preferably used. This cosmetic for hair also has a long-acting prevention effect on damage to hair.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a cosmetic that improves a defect that a colored cosmetic in a transparent container has an excellent appearance but poor light resistance and fading and change of color occur by light.  &lt;P&gt;SOLUTION: The cosmetic comprises a tar coloring matter, an organic ultraviolet light absorber and condensation type persimmon tannin. The amount of the organic ultraviolet light absorber mixed is preferably 0.001-0.5 wt.%, more preferably 0.01-0.1 wt.%. The amount of the condensation type persimmon tannin is preferably 0.0005-0.25 wt.%, more preferably 0.005-0.05 wt.%. The cosmetic has excellent light resistance and a vivid color.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
PROBLEM TO BE SOLVED: To obtain a hair dressing composition capable of spreading over hair near the scalp by forming a mist in jetting using a stock solution for hair dressing and a propellant, attaching the mist to hair and then foaming the mist and rapidly defoaming to form a liquid. SOLUTION: This hair dressing composition is obtained by using 55-97wt.% stock solution composed of 0.3-10wt.% base for hair dressing, 1-70wt.% monovalent lower alcohol and 25-98wt. % water and 3-45wt.% propellant containing &gt;=70wt.% liquefied petroleum gas. Aresin for hair dressing (e.g. anionic resin or cationic resin) or cellulosic thickener (e.g. hydroxyethyl cellulose or carboxymethyl cellulose) is preferably used as the base for hair dressing. For example, ethanol, normal propyl alcohol or the like is used as the monovalent lower alcohol. The composition for hair dressing has preferably 2kg.G/cm&lt;2&gt; , especially preferably 4-7kg.G/cm&lt;2&gt; pressure. The composition is free from unpleasant odor and does not erode a vessel made of a metal.
The present invention relates to novel amyloid binding compounds of formula (I) and methods for measuring effects of the compounds, by measuring changes of amyloid plaque level in living patients. More specifically, the present invention relates to a method of using the compounds of this invention as tracers in positron emission tomography (PET/) imaging to study amyloid deposits in brain in vivo to allow diagnosis of Alzheimer&#39;s disease. Thus, the present invention relates to use of the novel amyloid binding compounds as a diagnostic. The invention further relates to a method of measuring clinical efficacy of Alzheimer&#39;s disease therapeutic agents. Specifically, the present invention relates to novel aryl or heteroaryl substituted azabenzoxazole derivatives, compositions, and therapeutic uses and processes for making such compounds. or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof, wherein: X is O or S; A and Y independently are N, or CH;
The present invention relates to nucleic acid molecules, including antisense and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNAzymes, Inozymes, Zinzymes, Amberzymes, and G-cleaver ribozymes, which modulate the synthesis, expression and/or stability of an HCV or HBV RNA and methods for their use alone or in combination with other therapies. In addition, nucleic acid decoy molecules and aptamers that bind to HBV reverse transcriptase and/or HBV reverse transcriptase primer sequences and methods for their use alone or in combination with other therapies, are disclosed. Oligonucleotides that specifically bind the Enhancer I region of HBV DNA are further disclosed.  The present invention further relates to the use of nucleic acids, such as decoy and aptamer molecules of the invention, to modulate the expression of Hepatitis B virus (HBV) genes and HBV viral replication. Furthermore, HBV  animal models and methods of use are disclosed, including methods of screening for compounds and/or potential therapies directed against HBV. The present invention also relates to compounds, including enzymatic nucleic acid molecules, ribozymes, DNAzymes, nuclease activating compounds and chimeras such as 2&#39;,5&#39;-adenylates, that modulate the expression and/or replication of hepatitis C virus (HCV).
PURPOSE:To obtain the titled agent free from side effect such as hepatic disorder and having excellent effect, by using one or more compounds selected from 9,12,15-cis-octadecatrienoic acid and 5,8,11,14-cis-eicosatetraenoic acid as an active component. CONSTITUTION:The objective agent contains one or more compounds selected from 9,12,15-cis-octadecatrienoic acid, its acid derivative, 5,8,11,14-cis- eicosatetraenoic acid and its acid derivative as active components. The above active compound is mixed with a conventional preparation raw material such as gelatin, casein or lactose and formed in the form suitable for oral administration or subcutaneous injection, etc. (e.g. capsule or tablet). The amount of the active compound in the drug preparation is &gt;=0.1g per 1kg of the body weight. The active compound is present at a small amount as a fatty acid composition in natural oils and fats such as linseed oil or soybean oil.
Prepns. consist of a soln. of a water-soluble salt of thyroxine substance and contain is not 50% water. Thyroxine substance is present in a concentration of &gt;0.5 mg/ml., and the soln. additionally contains vitamin B12 in the same amt. as the thyroxine substance. The soln. is free from macromolecules and macro-ions. The gelling agents used in parent patent can be omitted from the formulation without adversely affecting stability, so that higher thyroxine does can be administered without the problems associated with high viscosity. In an example, parenteral formulation is prepd. by dissolving 120 g crystalline vitamin B12 and 120 mg sodium DL-thyroxine in 100 ml 0.9% NaCl solution.
A composition for preventing and treating Alzheimer disease is provided to reduce accumulation of amyloid beta-protein lower saturated fatty acid without side effect. A composition for treating and preventing Alzheimer&#39;s disease comprises a monacolin isolated from red mold rice, anti-inflammation agent, antioxidant compound. The active minimum content of monacolin is 100mug per 1 g of red mold rice. The active minimum content of antioxidant compound is more than 40mug per 1g of red mold rice. The antioxidant compound is a dimerumic acid, tannin, phenol compound, monounsaturated fatty acid, sterols or superoxide dismutase(SOD). A method for manufacturing the composition for preventing and treating Alzheimer&#39;s disease comprises: a step of washing and sterilizing rice seed under the high pressure and high temperature; a step of culturing Monascus purpureus in medium; a step of stirring medium and providing moisture;; a step of stirring under the specific temperature and afterripening; a step of collecting fermented product of red mold rice and drying; a step of pulverizing the fermented product; and a step of resolving the fermented product in water.
Aerosol compositions comprise a solution of at least one salt of a therapeutically active amine having a pKa value of at least 7.8 with a C4- 18 saturated, unsaturated or hydroxy-substituted monocarboxylic acid.  An extensive list of amines having therapeutic value is given including examples of ethanol-amine, ethylene diamine and ephedrine derivatives.  The compositions may include a finely-divided therapeutic solid examples of which include r-epinephrine hydrochloride, proteolytic enzyme concentrate, penicillin G procaine, talc and isoproterenol sulphate.  Propellants specified are isobutane, isobutane/propane, ethyl chloride and various &#34;Freons&#34; (Registered Trade Mark) and mixtures thereof.ALSO:The invention comprises the oleate, laurate, myristate and stearate of chlorpheniramine, which are prepared by direct action of the free acid on the free base.ALSO:Pharmaceutical aerosol compositions comprise a solution in a liquid aerosol propellant of at least one salt of a therapeutically active amine having a pKa valve of at least 7.8 with a saturated, unsaturated or hydroxy-substituted C4-18 monocarboxylic acid.  A large number of antihistaminic and adrenergic amines are specified including ethanolamine derivatives of the structure:  &lt;FORM:1040731/A5-A6/1&gt; in which R1 is an aromatic radical and R2 + R3 are alkyl (e.g. diphenhydramine, doxylamine, carbinoxamine, &amp;c.); ethylene diamine derivatives of the structure: &lt;FORM:1040731/A5-A6/2&gt; where R1 is an aromatic ring and R2 is an aliphatic, cycloaliphatic or aromatic group (e.g. methaphenilene, pyrilamine, tripelennamine, thonzylamine, &amp;c.); pheniramine, chlorpheniramine, and other propylamine derivatives; ephedrine and its derivatives and other amines e.g. cyclizine, meclizine, clemizole and phenindamine, &amp;c.  A solid therapeutic material may also be present, e.g. r-epinephrine hydrochloride, proteolytic enzyme concentrate, penicillin G procaine, talc and isoproterenol sulphate.
&#34;Mercapto acyl-carnitines, process for their preparation and pharmaceutical compositions containing same&#34;.     Abstracts of the disclosures A novel class of mercapto acyl-carnitines is disclosed, wherein the mercapto acyl radical is the radical of saturat-ed mercapto acids having from 2 to 10 carbon atoms. These mercapto acyl-carnitines are prepared e.g. by first preparing the corresponding halogen acyl-carnitine and then substitut-ing therein, by nucleophylic substitution, the -SH group for the halogen atom.    These mercapto acyl-carnitines are useful therapeutic agents, e.g. for the treatment of intoxications and burns and as mucolytic agents.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide rigid capsules intended for coloration of their own for preventing misuse and production convenience(securing discrimination).  &lt;P&gt;SOLUTION: The rigid capsules having specks-free neat color tone and gloss are obtained by using a condensed phosphate salt in making a coloration with a natural coloring matter (especially a flavonoid-one). The cause of developing above-mentioned specks is that, when used a flavonoid-based coloring matter, it is bound to extremely minute amounts of metal ions inevitably contaminated from raw materials and/or production process system to effect forming colored and hard-to-dissolve salt(s). By adding the condensed phosphate salt, such hard-to-dissolve salt formation can be prevented. The rigid capsules can be used for pharmaceuticals or foods, being very useful.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To obtain a composition for oral cavity having high dispensability of preparation and high permeability, permeating the preparation to every corner in an oral cavity, capable of efficiently preventing oral cavity diseases. SOLUTION: A composition for oral cavity containing &gt;=0.1 wt.% based on the whole composition of a nonionic surfactant and one or more of an imidazolium betaine type ampholytic surfactant as an ampholytic surfactant, an acyl/dialkylethylenediamine derivative and an N-alkylamino acid derivative but not a polishing agent having &lt;=35 dyne/cm surface tension is mixed with air by applying a pressing force to contents and packed into a nonaerosol type nongas normal-pressure container. A liquid dosage form can be made foamy in use, readily placed on a toothbrush and used. The composition has a good feeling in use by lubricating actions of foams. Since a proper amount of foams having excellent shape retention is continued, brushing is readily carried out for a long time.  The composition has no problem with respect to time in use, safety and environmental aspects in waste treatment since a nongas normal- pressure container can be used.
&lt;P&gt;PROBLEM TO BE SOLVED: To produce a functional food obtained by taking various kinds of minute amount of (metal element) mineral waters capable of activating cells for preventing, treating and curing various kinds of diseases such as geriatric diseases, lifestyle-related diseases, viral diseases, allergic diseases from ores.  &lt;P&gt;SOLUTION: Humans are subject to diseases even if any of five big nutrients such as hydrocarbons, proteins, fats, minerals and vitamins is deficient. The minerals can not be created in human bodies. cereal crops and livestock products using the crops as feed continue to be short of these minerals and humans eating those are also short of minerals in an inorganic agricultural method which is a present agricultural policy. As a result, since cell activity cannot perform normal activity, humans cannot get over diseases even if when any time comes. Therefore, it becomes important to directly utilize minerals from ores. Minerals are taken from ores. Many kinds of high-purity minerals are contained in good balance in these ores. Force for getting over diseases is stored in human bodies by pulverizing these ores with a pulverizer, dissolving these pulverized ores in a sulfuric acid solution, diluting the ionized solution with water and taking the mineral water for drinking into human bodies.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a data base system capable of easily providing knowledge regarding medical care corresponding to symptoms.  &lt;P&gt;SOLUTION: In a storage part 101, a related phrase and disease condition combination information 111 in which a plurality of disease condition related phrases related to disease conditions are combined with each disease condition phrases included in a plurality of disease condition phrases indicating the disease conditions respectively is stored. In response to information input by a user, symptom information concerning a sentence in which the symptoms are described is accepted by a server control part 102. Next, two or more combinations of the disease condition related phrases having predetermined relation from the symptom information are recognized by predetermined language analysis processing by a natural sentence analysis part 122. Then, one or more disease condition phrases corresponding to the two or more combinations of the disease related phrases recognized by the natural sentence analysis part 122 are detected from the related phrase and disease condition combination information 111 by a disease condition detection part 124.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
The invention disclosed herein is directed to methods of identifying a polypeptide suitable for epitope liberation including, for example, the steps of identifying an epitope of interest; providing a substrate polypeptide sequence including the epitope, wherein the substrate polypeptide permits processing by a proteasome; contacting the substrate polypeptide with a composition including the proteasome, under conditions that support processing of the substrate polypeptide by the proteasome; and assaying for liberation of the epitope. The invention further relates to vectors including a housekeeping epitope expression cassette. The housekeeping epitope(s) can be derived from a target-associated antigen, and the housekeeping epitope can be liberatable, that is capable of liberation, from a translation product of the cassette by immunoproteasome processing. The invention also relates to a method of activating a T cell comprising contacting a substrate polypeptide with an APC and contacting the APC with a T cell. figure 1. pMA2M ISS (3) &amp;NIS (7) CMVp (1) pMB ori rev (6) 3315 bp BGH poly A (4) Kan R( Figure Legend: Code in Figure Genetic Element Region I-CMVp Cytomeglovirus Enhancer/Promotor- 63-637 2. SAbs&#39;\ s cot. 696-983 . SeC t.~~I £fTrOPL . 3. ISS Immunostimulatory Sequence 3220-3226 4. BGH poly A&#39; Bovine Growth Hormone 1028-1045 Polyadenylation Signal 5. Kan R Kanamycin Resistance Gene 1431-2225 6. pMB ori rev Bacterial pMB Origin of Replication 3165-2492 7. NIS Nuclear Import sequence from 3227-3304 Simian Virus 40-72bp repeat